safety findings of long-term bevacizumab for patients with ovarian cancer
Published 6 years ago • 1K plays • Length 1:15Download video MP4
Download video MP3
Similar videos
-
0:45
results for combination bevacizumab plus mirvetuximab soravtansine in ovarian cancer
-
1:05
dr. essel discusses long-term bevacizumab in ovarian cancer
-
4:25
adjuvant chemotherapy bevacizumab for ovarian cancer
-
7:32
bevacizumab for recurrent ovarian cancer
-
7:19
combination therapy with niraparib and bevacizumab for ovarian cancer
-
1:00
rationalizing use of pembrolizumab/bevacizumab in recurrent ovarian cancer
-
0:47
bevacizumab for the treatment of patients with ovarian cancer exhibiting poor chemosensitivity
-
6:34
bevacizumab’s value in recurrent ovarian cancer
-
3:47
frontline bevacizumab strategies in ovarian cancer
-
0:52
dr. mirza on safety profile of niraparib/bevacizumab in recurrent ovarian cancer
-
3:16
dr. michael birrer on bevacizumab in ovarian cancers
-
6:04
when to add bevacizumab for recurrent ovarian cancer
-
1:12
dr. herzog on the optimal use of bevacizumab in patients with ovarian cancer
-
3:47
gog-0218: which patients with ovarian cancer experience highest benefit from 1l bevacizumab?
-
1:40
dr. hardesty on bevacizumab/parp inhibitor combination in ovarian cancer
-
6:01
olaparib and bevacizumab: on the horizon for treating ovarian cancer
-
1:54
dr. burger on ovarian cancer maintenance therapy with bevacizumab
-
0:50
challenges with targeted therapies in ovarian cancer